Amneal Pharmaceuticals, Inc. (AMRX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-05

Key Insights

Nikita Shah, the Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), has exercised a significant number of restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) on March 3, 2026, indicating their confidence in the company's long-term growth.
The filing shows that Shah has sold a portion of the shares acquired through the vesting of RSUs and PRSUs, likely to cover tax withholding obligations, while retaining a substantial number of shares, suggesting their continued alignment with shareholders.
The vesting of the PRSUs was triggered by the company's stock price achieving certain performance targets, which could signal strong financial performance and positive market sentiment towards Amneal Pharmaceuticals.

Want the newest filings?

This analysis covers the filing from 2026-03-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-05

The reporting person, Andrew S. Boyer, who is the Executive Vice President of Amneal Pharmaceuticals, Inc. (AMRX), has engaged in a series of transactions involving the vesting and settlement of restricted stock units and performance-based restricted stock units.
The transactions indicate that the reporting person is holding a significant amount of Amneal's Class A Common Stock, with a total beneficial ownership of over 400,000 shares following the reported transactions.
The vesting and settlement of the performance-based restricted stock units suggest that the company has met certain performance targets, which could be a positive indicator for the company's financial and operational performance.

Filed: 2026-03-05

The reporting person, Tasos Konidaris, Executive Vice President & CFO, significantly increased his stake in Amneal Pharmaceuticals through the vesting of restricted stock units and performance-based restricted stock units.
Konidaris exercised a total of 630,865 restricted stock units and 458,716 performance-based restricted stock units, resulting in the acquisition of 1,089,581 shares of Amneal's Class A common stock.
The significant insider buying by the CFO suggests a positive outlook on the company's future performance and could signal confidence in the company's growth prospects.

Filed: 2026-03-05

Insider Jason B. Daly, EVP and Chief Legal Officer, has exercised a significant number of restricted stock units and performance-based restricted stock units, acquiring over 300,000 shares of Amneal Pharmaceuticals' Class A common stock.
Daly has also sold a portion of the acquired shares to cover tax withholding obligations, indicating potential liquidity needs or portfolio diversification.
The vesting and subsequent sale of these equity awards suggest that Daly may have confidence in Amneal's future prospects and aligns his interests with shareholders.

Filed: 2026-03-05

Insider Chirag K. Patel, President & Co-CEO, exercised 752,568 stock options and restricted stock units, indicating confidence in the company's future performance.
Patel sold 313,153 shares to cover tax withholding obligations, suggesting he is holding a significant portion of his equity stake in the company.
The vesting of the performance-based restricted stock units, with a 200% payout, suggests the company has achieved strong financial results over the past three years.

Filed: 2026-03-05

Insider Chintu Patel, who serves as Co-CEO, has exercised a significant number of restricted stock units (RSUs) and performance-based RSUs, indicating his confidence in the company's future prospects.
Patel has sold a portion of the shares acquired through the vesting of RSUs and performance-based RSUs to cover tax withholding obligations, suggesting he is not looking to immediately cash out his holdings.
The company has awarded Patel additional RSUs, further aligning his interests with those of shareholders and suggesting the board's continued confidence in his leadership.

Other reports for Amneal Pharmaceuticals, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.